Logo Image
News|Articles|March 27, 2026

Nordic Cold Chain Solutions Launches Lab to Meet GLP-1 Demand

The facility addresses growing demand for GLP-1 medications and other temperature-sensitive pharmaceuticals.

Nordic Cold Chain Solutions (NCCS) has announced the launch of its GLP-1 & Small-Format Packaging Innovation Lab, a facility dedicated to supporting pharmaceutical manufacturers, specialty pharmacies, and e-commerce leaders as they navigate the logistical challenges associated with temperature-sensitive medications.¹ The initiative formalizes the company's hands-on approach to developing and scaling cold chain packaging solutions tailored specifically for parcel and small-format distribution channels, an increasingly important segment of the healthcare supply chain.¹ This development comes at a time of sustained growth in the global pharmaceutical cold chain packaging market.²

How Does the Innovation Lab Support the Full Pharmaceutical Packaging Lifecycle?

The Innovation Lab is designed to scale in parallel with rising demand, offering support across the full product lifecycle—from early-stage product development and pilot programs to high-volume production and shipping.¹ By centralizing packaging design, testing, and validation capabilities, NCCS aims to help its partners streamline the process of bringing temperature-sensitive therapies to market while maintaining the required performance and compliance standards.¹ The facility reflects a structured approach to addressing the complexities of pharmaceutical distribution, particularly for therapies that depend on strict thermal control throughout transit.¹

"As the GLP-1 landscape continues to evolve at unprecedented speed, our customers need partners who can move just as fast," said Keith Baechle, chief commercial officer of NCCS, in a company release. "This lab is an extension of our customer-first mindset—bringing our engineering expertise, industry knowledge, and hands-on experience together to help customers adapt quickly and scale confidently."¹

Why Is Standardized Cold Chain Pack-Out Design Critical for GLP-1 Medications?

A key focus of the lab is the standardization of pack-outs for mailers and compact shippers.¹ According to NCCS, this effort is intended to improve consistency across packaging configurations while also reducing the time required to move from concept to scalable production.¹ Standardized pack-outs can help ensure repeatable thermal performance, which is essential for maintaining product integrity in regulated pharmaceutical environments. The ability to accelerate development timelines without sacrificing quality is particularly relevant as companies manage increasing volumes of temperature-sensitive shipments.

The lab's operational scope includes pack-out design, product development, and ISTA-certified laboratory testing.¹ These capabilities are structured to align with the documentation requirements and quality expectations typical of regulated healthcare supply chains. NCCS also noted that the facility follows operations aligned with AIChE and URAC standards.¹

What Are the Cold Chain Requirements for GLP-1 Therapies?

The focus on glucagon-like peptide-1 (GLP-1) therapies highlights a specific area of growing demand within the pharmaceutical market. These medications, which are used for diabetes management and weight loss, require precise temperature control during storage and transportation to maintain therapeutic efficacy.¹ The Innovation Lab is intended to help stakeholders address these requirements through validated packaging solutions and standardized processes designed for consistent performance.¹

How Quickly Is the Pharmaceutical Cold Chain Packaging Market Growing?

The launch of the NCCS Innovation Lab aligns with strong growth projections for the pharmaceutical cold chain packaging sector. According to industry analysis, the global market was valued at $9.26 billion in 2025 and is expected to reach $10.36 billion in 2026.² Looking further ahead, the market is projected to grow to $26.41 billion by 2034, representing a compound annual growth rate of 12.41%.²

This expansion is being driven by increasing demand for biopharmaceutical products, including insulin, vaccines, monoclonal antibodies, and cell and gene therapies.² These therapies often require strict temperature control to preserve stability and effectiveness, making reliable cold chain packaging a critical component of the supply chain. The growing adoption of GLP-1 medications has further contributed to this demand, increasing the need for packaging solutions capable of maintaining consistent thermal conditions during transit.²

The Innovation Lab builds on NCCS's earlier introduction of the Nordic Express Pack, described as the first cold chain packaging solution specifically designed and tested for GLP-1 medications.² This solution was developed to address the strict temperature requirements associated with these therapies, ensuring that products remain within defined temperature ranges during transit.²

By combining product innovation with structured testing and validation capabilities, the company is positioning itself to address the evolving demands of the cold chain packaging market while maintaining alignment with industry standards and regulatory expectations.¹

References

Related Content